3.367 kb deletion. This deletion abolishes exon 3 and is the first described single exon deletion within TCOF1 . On RNA level we observed loss of this exon which supposedly leads to haploinsufficiency of TREACLE, the nucleolar phosphoprotein encoded by TCOF1. Copyright © 2012 S. Karger AG, Basel Treacher Collins syndrome (TCS, OMIM 154500) is a rare craniofacial disorder with an incidence of about 1 in 50,000 live births [Posnick and Ruiz, 2000] . It is characterized by craniofacial anomalies like down-slanting palpebral fissures often accompanied by lower eyelid colobomas and a paucity of eyelashes medial to the defect, cleft palate, hypoplasia of mandible and zygomatic complex, as well as external and middle ear defects and conductive hearing loss [Dixon et al., 2007] .
Lich /Prager /Lohmann /Wieczorek Mol Syndromol 2011; 2:53-59 54 no causative mutation has been found so far [Splendore et al., 2000; Teber et al., 2004; Horiuchi et al., 2005; Masotti et al., 2005] .
TCOF1 encodes for the nucleolar phosphoprotein TREACLE which is involved in ribosomal biogenesis as are the proteins encoded by POLR1D and POLR1C [Larkin and Guilfoyle, 1997; Wise et al., 1997; Isaac et al., 2000; Valdez et al., 2004; Dixon et al., 2006] . Haploinsufficiency for Treacle in mice led to a reduced production of mature ribosomes thus causing restriction of cell cycle progression, reduced proliferation and high levels of apoptosis of the normally highly proliferative cranial neural crest cells from which facial bones and cartilages are derived [Dixon et al., 2006; Jones et al., 2008] . A reduction of the number of these cells at a critical time point early in embryogenesis leads to the cranial malformations typical for TCS [Dixon et al., 2007; Trainor, 2010] . In humans the phenotype shows a high inter-and intrafamilial variability ranging from mild, sometimes unaffected mutation carriers to severe forms leading to intrauterine death Splendore et al., 2002; Dixon et al., 2004; Teber et al., 2004; Masotti et al., 2005] . The spectrum of mutations within the TCOF1 gene that causes TCS is very heterogeneous The Treacher Collins Syndrome Collaborative et al., 1996; Splendore et al., 2002 Splendore et al., , 2005 So et al., 2004; Teber et al., 2004; Horiuchi et al., 2005; Dixon et al., 2007; Masotti et al., 2009] . The majority of the mutations are insertions and deletions of up to 40 nucleotides that result in premature termination codons Edwards et al., 1997; Ellis et al., 2002; Teber et al., 2004; Trainor et al., 2009] . Exon deletions or duplications in TCOF1 have not been published yet. Hitherto no obvious correlation between the type or location of the mutation and the phenotype could be observed [Trainor, 2010] .
We here report on a 3.367 kb deletion affecting exon 3 and neighboring sequences within TCOF1 in a woman with unequivocal clinical diagnosis of TCS.
Material and Methods

Material
Genomic DNA was isolated from EDTA whole blood using the Flexi Gene DNA Kit (Qiagen, Hilden, Germany) according to the manufacturer's protocol. Total RNA was isolated from blood using the PAXgene Blood RNA Kit (PreAnalitiX, Hombrechtikon, Switzerland) following the manufacturer's instructions. An additional DNAse treatment was conducted with RQ1 DNAse (Promega, Wisc., USA) according to the manufacturer's recommendations to remove remaining traces of genomic DNA. A written informed consent approved by the ethics committee of the Universitätsklinikum Essen, Germany (07-3321), was obtained from the patient and the father. No material was available from the deceased mother.
Mutation Analysis
Sequencing of the TCOF1 gene was performed as described previously [Teber et al., 2004] . In addition, mutation analysis of the POLR1C and POLR1D genes, the 2 recently identified genes causative for TCS, was also performed as published before [Dauwerse et al., 2011] .
Microarray Analysis
A (genome-wide) copy number analysis was conducted using the Affymetrix genome-wide human SNP array 6.0 (Affymetrix, Santa Clara, Calif., USA). The array was processed according to the manufacturer's instructions and data analysis was performed using the Genotyping Console software (Affymetrix).
Multiplex Ligation-Dependent Probe Amplification
Gene dosage of 25 exons of the TCOF1 locus was further analyzed by multiplex ligation-dependent probe amplification (MLPA) using the SALSA MLPA KIT P310-B1 TCOF1 (MRC Holland, Amsterdam, The Netherlands) (missing exons 9, 21 and 22; see manual). Hybridization, ligation and polymerase chain reactions (PCR) were carried out according to the manufacturer's instructions. Amplification products were analyzed by capillary electrophoresis using the ABI3100 capillary sequencer. Data analysis was carried out using the Gene Marker Software (Softgenetics, State College, Pa., USA).
Identification of the Breakpoints via Long-Range PCR (and Sequencing)
To confirm the deletion and to identify its breakpoints, a long-range PCR using the Expand long-range dNTPack (Roche, Mannheim, Germany) was performed using the primers F: 5 -GTGCTGGGGATTAATTGTGG-3 and R: 5 -CCCATAGGC A-ATAGCTTGGA-3 which generate a 6,840 bp product if a wildtype allele is present. The PCR protocol was used as stated in the manufacturer's manual using a magnesium-chloride (MgCl 2 )-containing buffer, a final primer concentration of 0.6 M , no DMSO and about 500 ng of genomic DNA. The PCR was carried out on a Veriti cycler (Applied Biosystems, Foster City, Calif., USA) with the PCR conditions: first denaturation at 95 ° C for 2 min, then 10 cycles with 95 ° C for 10 s, 60 ° C for 15 s and 68 ° C for 7 min followed by 20 cycles of 95 ° C for 10 s, 60 ° C for 15 s and 68 ° C for 7 min plus 20 s in each cycle and a final elongation step of 7 min.
Sequencing of the breakpoints was performed using an additional primer (F_Seq: 5 -AGTGGGTAGAGAGTGGCAGG-3 ) after ExoSap-It purification (USB, Ohio, USA, see manual) with the BigDye Terminator v1.1 Cycle Sequencing Kit on an ABI-3100 automatic capillary genetic analyzer (Applied Biosystems). For sequence analysis we used the software Sequencing Analysis (Applied Biosystems) and Geneious (Biomatters, Auckland, New Zealand).
mRNA Analysis
Reverse transcriptase (RT)-PCR was conducted according to standard protocols, followed by a PCR using primers spanning exons 1-4 of TCOF1 (F_Ex1: 5 -CTTCCCCTGATCTACCACCA-
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Mol Syndromol 2011;2:53-59 55 3 and R_Ex4: 5 -CCAGTCTTGCCAGCTTTCTC-3 ). The PCR was carried out using AmpliTaq Gold (Applied Biosystems) and a touchdown PCR program [Zeschnigk et al., 2009 ] modified as follows: first denaturation at 95 ° C for 5 min, 14 cycles with 95 ° C for 20 s, annealing for 30 s with temperature decreasing 0.5 ° C each cycle starting from 66 ° C and elongation for 30 s at 72 ° C followed by 35 cycles with 95 ° C for 20 s, 59 ° C for 30 s and 72 ° C for 30 s and a final elongation for 5 min at 72 ° C. An amplification of an RNA-specific product for the ACTB gene was carried out to exclude a contamination with genomic DNA [Kanber et al., 2009] . The 2 obtained cDNA amplicons were gel purified using the QIAquick gel extraction Kit (Qiagen) according to the manufacturer's instructions. The PCR primers F_Ex1 and R_Ex4 were used for sequencing.
Results and Discussion
Clinical Report
We investigated a cohort of 112 patients with a tentative clinical diagnosis of TCS. All patients were selected after negative screenings for mutations in the TCOF1 , POLR1D and POLR1C genes.
The patient was born at term with normal birth measurements to nonconsanguineous, healthy parents. Family history is unremarkable. She reached her developmental milestones in a normal range: Sitting with 6 months, walking without support at the age of 15 months and speaking first words at the age of 12 months. She presented with a classical TCS phenotype showing down-slanting palpebral fissures, a right-sided lower eyelid coloboma with absence of eyelashes medial to the defect, hypoplasia of the zygomatic complex as well as conductive deafness and median cleft palate (see fig. 1 and Teber et al. [2004] patient M18662). She had normal external ears, but the middle ear lacked the ambos. Cleft palate was surgically corrected at the age of 6 years, reconstructive surgery of lower eyelid coloboma, middle ear anomalies and zygomatic hypoplasia were performed at the age of 7, 11 and 16 years, respectively.
According to the severity score based on clinical findings introduced by Teber et al. [2004] , the patient is severely affected with 12 out of 20 points.
Molecular Analyses
MLPA analyses of TCOF1 in a cohort of 112 patients with a tentative clinical diagnosis of TCS showed an aberrant result in 1 patient (M18662) only. Here a reduced dosage for the probe representing exon 3 ( fig. 2 ) was observed in the patient but not in her healthy father. No material of the deceased mother was available for analysis. The nature of the aberrant MLPA result was further analyzed by long-range PCR and sequencing of the deletion junction fragment led to the identification of the breakpoints and revealed a 3.367 kb deletion abolishing the entire exon 3 and neighboring sequences of introns 2 and 3 (chr5: 149,741,531-149,741,534 : 149,744,897-149,744 ,900; GRCh37/hg19; 3 bp flanking the breakpoints cannot exactly be assigned either to the proximal or distal deletion breakpoint, see fig. 3 ). A previously conducted Affymetrix genome-wide SNP array 6.0 showed no aberrant results in this area due to scarcity of probes (in this region) (results not shown).
To further investigate the effect of the deletion on RNA level expression analysis was performed. Both expression of a transcript lacking exon 3 and the wild-type transcript were observed in RNA from peripheral blood of the patient ( fig. 4 a) . Sequence analysis confirmed that exon 2 was directly spliced onto exon 4 ( fig. 4 b) . Fig. 1 . The patient at the age of 26 years, showing the characteristic facial anomalies of TCS: down-slanting palpebral fissures, a lower eyelid coloboma, hypoplasia of the zygomatic complex and low-set, small ears. Earlier photographs were published previously [Teber et al., 2004] . point (chr5: 149,741,531-149,741,534 : 149,744,897-149,744 ,900, GRCh37/hg19). For comparison, part of the wild-type sequence is shown above.
The deletion leads to a frameshift on protein level and a premature stop codon in exon 5 (p.Gln55His fs X73, according to reference AAR87774, fig. 4 b and online suppl. fig. 1 ; for all online supplementary material, see www.karger.com/doi/10.1159/000335545). This is due to the fact that the last 2 nucleotides of exon 2 and the first nucleotide of exon 3 contribute to 1 codon (CAA: p.Gln55) and, in addition, the last nucleotide of exon 3 forms a codon with the first 2 nucleotides of exon 4 (ACC: p.Thr102). Introduction of a premature stop codon is the most frequent outcome of mutations in TCOF1 and probably leads to haploinsufficiency of TREACLE [Dixon et al., 2006 [Dixon et al., , 2007 Gladwin et al., 1996] . Premature stop codons can lead to the translation of a truncated protein or to nonsense-mediated decay (NMD) of the mRNA [Cartegni et al., 2002] . Isaac et al. [2000] could not detect truncated proteins in fibroblasts of TCS patients, thus suggesting NMD. In contrast, Marsh et al. [1998] could show mislocalization of human TREACLE after introduction of 3 different truncating mutations into TCOF1 using the (African green monkey) cell line COS-1. Only for one of the inserted mutations, which terminates TREACLE at amino acid position 36, no protein could be detected [Marsh et al., 1998 ]. Expression studies on RNA level also showed ambiguous results. Masotti et al. [2009] investigated samples from 4 TCS patients with different mutations on RNA level. They detected aberrant transcripts in 2 of these samples, one of them carrying a mutation within exon 3 (4 bp insertion). They argued that NMD might not be the only mechanism regulating transcription. It is also possible that the kind of mechanism is somehow linked to the position of the mutation. However, in the case of our patient the detection of an aberrant transcript argues against complete NMD. Most of the mutations identified in TCOF1 so far are point mutations or very small deletions which do not exceed a length of a few base pairs Splendore et al., 2000 Splendore et al., , 2002 Teber et al., 2004; Horiuchi et al., 2005; Masotti et al., 2005] . The largest deletion yet identified spanned 40 nucleotides and was located in exon 20 [Ellis et al., 2002] , whereas the large deletion reported here spans about 3 kb. Its size seems to have no influence on the phenotype as the patient is not more severely affected than other TCS patients [Teber et al., 2004] and shows no additional symptoms. This is in concordance with the previously described lack of correlation between the phenotype and the type and location of the mutation [Trainor, 2010] .
Although the patients in the investigated cohort are clinically not characterized in much detail, our results suggest that the frequency of such large deletions within TCOF1 seems to be rather low (1 in 112 patients ; 0.9%) despite covering 25 of the known 28 exons of TCOF1 with the MLPA Kit used. More studies will be needed to estimate a more exact frequency. Nevertheless, analyses like MLPA that are capable of detecting larger deletions should be considered for TCS diagnostic in patients without point mutations or very small deletions and insertions in TCOF1 , POLR1D and POLR1C.
Conclusions
This is the first report about a deletion within the TCOF1 gene identified by MLPA. The deletion is the largest one described so far in TCS patients. It spans 3.367 kb, abolishes the entire exon 3 and leads to a premature stop codon in exon 5 due to a frameshift. As expected from previous genotype/phenotype correlations, there seems to be no correlation between the size of the intragenic deletion, the phenotype and the severity of the phenotype. The frequency of large deletions seems to be rather low, although more studies are needed to estimate a more exact frequency. Analyses capable of detecting larger deletions should be considered for TCS diagnostic in patients without point mutations in TCOF1 , POLR1D and POLR1C.
